The TMPRSS2 (Transmembrane Protease Serine Subtype 2) prevention bromhexine hydrochloride (BRH) and the NLRP3 inflammasome inhibitor colchicine have happened studied in a number of dispassionate trials accompanying contradictory results. We started the situation of Covid-19 outpatients and inpatients with the standard colchicine doses and establish no effect. BRH pills also did not present the expected result.That is reason, from May 2020 the colchicine doses in our treatment regime were increased while BRH was given inhaled. Our in addition 2 years of happening and unpublished results clearly display that the immediate presidency of BRH by inhalation, in combination accompanying higher doses of colchicine to outpatients basically eliminates the risk of difficulties and hospital admission. Moreover, the threefold combination of inhaled BRH, optimum doses of Colchicine and hymecromone are an excellent means of lowering the mortality 'tween 4 and 5 times of inpatients with Covid-19. Starting situation as early as possible is intensely important. BRH is direct in prophylaxis if given for a very long time (e.g. a temporal length of event or entity's existence), especially before and during the real COVID-19 wave.Importantly, all three drugs are cheap and quickly available. Furthermore, bromhexine and hymecromone have practically no reactions.
Author(s) Details:
Vanyo Mitev,
Department of Medical Chemistry and Biochemistry, Medical University,
Sofia, Bulgaria.
Mondeshki Tsanko,
Department of
Propaedeutics of Internal Diseases, University Hospital Alexandrovska, Medical
University, Sofia, Bulgaria.
Krasimir Marinov,
Department
of Internal Medicine, Regional Hospital Trojan, Bulgaria.
Radoslav Bilyukov,
Department of Propaedeutics of Internal Diseases, University Hospital
Alexandrovska, Medical University, Sofia, Bulgaria.
Please see the link here: https://stm.bookpi.org/CODHR-V10/article/view/9402
No comments:
Post a Comment